IL95245A - Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and - Google Patents

Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and

Info

Publication number: IL95245A
Authority: IL; Israel
Prior art keywords: methyl; ondansetron; treatment; active ingredient; pharmaceutical composition
Prior art date: 1989-08-01

Application number

IL9524590A

Other languages

English (en)

Hebrew (he)

Other versions

IL95245A0 (en

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-01

Filing date

1990-07-31

Publication date

1995-03-15

1990-07-31 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1991-06-10 Publication of IL95245A0 publication Critical patent/IL95245A0/xx

1995-03-15 Publication of IL95245A publication Critical patent/IL95245A/en

Links

238000011282 treatment Methods 0.000 title claims abstract description 19
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 title claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
229960005343 ondansetron Drugs 0.000 claims abstract description 26
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 11
206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 7
239000012453 solvate Substances 0.000 claims abstract description 7
208000032841 Bulimia Diseases 0.000 claims abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
239000004480 active ingredient Substances 0.000 claims description 15
239000012458 free base Substances 0.000 claims description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
239000003826 tablet Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
150000001875 compounds Chemical class 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
208000035475 disorder Diseases 0.000 description 4
239000003814 drug Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
-1 phosphatas Chemical class 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000008354 sodium chloride injection Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
208000012672 seasonal affective disease Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
241000792859 Enema Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000002895 emetic Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
230000007160 gastrointestinal dysfunction Effects 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000036651 mood Effects 0.000 description 1
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000010004 neural pathway Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
230000037047 psychomotor activity Effects 0.000 description 1
238000010926 purge Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000003019 stabilising effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL9524590A 1989-08-01 1990-07-31 Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and IL95245A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898917556A GB8917556D0 (en)	1989-08-01	1989-08-01	Medicaments

Publications (2)

Publication Number	Publication Date
IL95245A0 IL95245A0 (en)	1991-06-10
IL95245A true IL95245A (en)	1995-03-15

Family

ID=10660972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9524590A IL95245A (en)	1989-08-01	1990-07-31	Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and

Country Status (8)

Country	Link
EP (1)	EP0411900A3 (de)
JP (1)	JPH03218311A (de)
KR (1)	KR910004190A (de)
CA (1)	CA2022379A1 (de)
GB (1)	GB8917556D0 (de)
IE (1)	IE902769A1 (de)
IL (1)	IL95245A (de)
ZA (1)	ZA905997B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225407A (en) *	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
WO1993000074A1 (en) *	1991-06-26	1993-01-07	Sepracor, Inc.	Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
GB9423511D0 (en) *	1994-11-22	1995-01-11	Glaxo Wellcome Inc	Compositions
WO2000051582A2 (en)	1999-03-01	2000-09-08	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
RU2162847C1 (ru) *	2000-07-14	2001-02-10	ООО с иностранными инвестициями "Редди-Биомед лимитед"	Способ получения ондансетрона и его фармацевтически приемлемых солей
CN104274395A (zh) *	2014-09-19	2015-01-14	威海爱威制药有限公司	盐酸昂丹司琼氯化钠注射液及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU895334D0 (en) *	1986-07-30	1990-01-28	Sandoz Ag	Process for the preparation of nasal pharmaceutical compositions

1989
- 1989-08-01 GB GB898917556A patent/GB8917556D0/en active Pending
1990
- 1990-07-31 KR KR1019900011701A patent/KR910004190A/ko not_active Withdrawn
- 1990-07-31 IE IE276990A patent/IE902769A1/en unknown
- 1990-07-31 JP JP2203757A patent/JPH03218311A/ja active Pending
- 1990-07-31 ZA ZA905997A patent/ZA905997B/xx unknown
- 1990-07-31 IL IL9524590A patent/IL95245A/en not_active IP Right Cessation
- 1990-07-31 CA CA002022379A patent/CA2022379A1/en not_active Abandoned
- 1990-07-31 EP EP19900308412 patent/EP0411900A3/en not_active Ceased

Also Published As

Publication number	Publication date
JPH03218311A (ja)	1991-09-25
EP0411900A3 (en)	1992-09-09
GB8917556D0 (en)	1989-09-13
KR910004190A (ko)	1991-03-28
ZA905997B (en)	1991-06-26
IL95245A0 (en)	1991-06-10
IE902769A1 (en)	1991-02-27
EP0411900A2 (de)	1991-02-06
CA2022379A1 (en)	1991-02-02

Legal Events

Date	Code	Title	Description
1997-04-15	RH	Patent void

Publication	Publication Date	Title
US4753789A (en)	1988-06-28	Method for treating nausea and vomiting
US4835173A (en)	1989-05-30	Method of medical treatment
US4845115A (en)	1989-07-04	Method of medical treatment
US4847281A (en)	1989-07-11	Method of medical treatment of addiction
AU633496B2 (en)	1993-02-04	Composition and method for treatment of gastrointestinal disorders
IL95245A (en)	1995-03-15	Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and
US5482716A (en)	1996-01-09	Medicaments
JP2834175B2 (ja)	1998-12-09	医薬
EP0269452A2 (de)	1988-06-01	Anwendung von Keton-Derivaten zur Herstellung von Arzneimitteln
US5276050A (en)	1994-01-04	Medicaments
US5221687A (en)	1993-06-22	Medicaments
JPH01250319A (ja)	1989-10-05	医薬
IE902768A1 (en)	1991-02-27	Medicaments
CA2022380A1 (en)	1991-02-02	Medicaments